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BACKGROUND: Colorectal cancer is one of the most common causes of cancer death worldwide. Using cDNA microarray containing
23040 genes, we earlier investigated gene-expression profiles in 11 colorectal cancers for the purpose of better understanding of
colorectal carcinogenesis as well as development of novel diagnostic and therapeutic strategies. MRG-binding protein (MRGBP)o r
C20orf20, encoding a subunit of TRRAP/TIP60-containing histone acetyltransferase complex, was up-regulated in the majority of
colorectal tumours.
METHODS AND RESULTS: The elevated expression of MRGBP was observed in colorectal cancer tissues by quantitative PCR as well as
immunohistochemical analyses. MRGBP marginally expressed in normal vital organs. Notably, suppressed MRGBP expression by
MRGBP short hairpin RNA inhibited proliferation of colorectal cancer cells. Yeast two-hybrid screening and subsequent
immunoprecipitation analysis identified bromodomain containing 8 (BRD8) as an MRGBP-interacting protein. As RNA interference
against BRD8 also suppressed proliferation of colorectal cancer cells, BRD8 may be an important down-stream target of MRGBP.
CONCLUSION: These results suggest that MRGBP has an important function in proliferation of cancer cells through the regulation of
BRD8 and that MRGBP should be a novel therapeutic target for colorectal cancer.
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Colorectal cancer is the second leading cause of cancer death in the
United States, and its incidence rates are increasing in Japan. It is
estimated that there are almost 500000 colorectal cancer-related
deaths every year in the world (Parkin, 2001). Although recent
medical advances have improved the prognosis of patients with the
disease, complete cure of patients with advanced tumour is far
from satisfactory. In chemotherapies for advanced colorectal
cancer, oxaliplatin/fluorouracil/leucovorin (FOLFOX) is an effec-
tive and well-tolerated regimen. Combination of targeted biological
agents such as anti-epidermal growth factor receptor (EGFR) with
FOLFOX have been reported to enhance the efficacy against EGFR-
expressing metastatic colorectal cancer (Giantonio, 2006; Taber-
nero et al, 2007). This indicates that the use of rationally selected
therapeutic agents will improve the treatment for advanced
diseases and results in increase of cure rate and/or prolonged
survival. Regarding colorectal cancer, combination chemotherapy
with Bevacizumab, an inhibitor of VEGF receptor, was approved in
the United States and was shown to be effective for 45% of patients
with colorectal cancer and increased their 1-year survival rate from
63.4% to 74.3% (Hurwitz et al, 2004). However, many patients are
still suffering and dying from the disease, and development of
additional molecular-targeted anti-cancer drugs is a matter of
pressing concern for public health.
These drugs target molecules that are expressed abundantly or
exclusively in cancer cells and functioning as an indispensable
factor for the growth or survival of cancer cells. For instance,
Imatinib (STI571) inhibits several protein kinases such as bcr-abl
fusion protein in chronic myelogenous leukaemia, and c-kit in
gastrointestinal stromal tumours (O’Dwyer and Druker, 2000).
Gefetinib targets the ATP cleft within the EGFR (Wakeling, 2002;
Fukuoka et al, 2003; Gridelli et al, 2003; Kris et al, 2003).
Trastuzumab is a monoclonal antibody to the HER2/neu receptor,
which is overexpressed in B30% of breast cancers (Molina et al,
2001). These drugs strikingly suppressed the growth of tumour
cells and showed minimum cytotoxic effect in normal cells.
Therefore, for the development of molecular-targeted anti-cancer
drugs pinpointing cancer cells, identification of molecules that are
expressed abundantly in cancer cells and clarification of their
function are essential.
Molecular studies have clarified that multiple-step process has
an important function in colorectal carcinogenesis, which involves
activation of oncogenes such as K-ras, and inactivation of tumour
suppressor genes such as p53 and APC. In addition to these genetic
changes, alteration of gene expression is involved in the
carcinogenesis. Epigenetic alterations including aberrant DNA
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smethylation and/or histone modification have been recently shown
to participate in some of the deregulated gene expression. To
unveil the molecular mechanisms of colorectal cancer and discover
target molecules for the development of novel anti-cancer drugs,
we analysed global gene-expression profiles of colorectal tumours
by cDNA microarray analysis representing 23040 genes (Lin et al,
2002). These efforts have identified a number of genes, which are
frequently either up-regulated or down-regulated in the tumours
compared with the corresponding non-cancerous tissues. Among
the list of genes up-regulated in the tumours, we found a gene
termed as MRG-binding protein (MRGBP), with an approved
symbol of chromosome 20 open reading frame 20 (C20orf20),
which was identified as a component of TRRAP/TIP60 histone
acetyltransferase complex and shown to bind directly to MRG15
and MRGX proteins (Cai et al, 2003). In this report, we show, for
the first time, that MRGBP expression was frequently elevated in
colorectal cancer, and that it has an important function in the
growth of cancer cells. These findings should contribute to a better
understanding of colorectal tumourigenesis, and may serve as a
starting point for the development of novel strategies for
prevention and treatment of colorectal cancer.
MATERIALS AND METHODS
Cell lines and tissue specimens
A human embryonic kidney cell line, HEK293, a monkey kidney
cell line, COS7, and human colon cancer cell lines, SW480 and
HCT116, were obtained from the American Type Culture
Collection (Manassas, VA, USA). All cells were grown in
monolayers in appropriate media as follows: Dulbecco’s modified
Eagle’s medium for HEK293 and COS7, McCoy’s 5A medium for
HCT116, and Leibovitz’s L-15 for SW480. All media were
supplemented with 10% fetal bovine serum and 1% antibiotic/
antimycotic solution (Sigma, St Louis, MO, USA). All colorectal
cancer tissues and corresponding non-cancerous tissues were
obtained with informed consent from surgical specimens of
patients who underwent surgery.
Isolation of RNA and quantitative PCR
Total RNA was extracted with RNeasy kit (Qiagen, Valencia, CA,
USA) according to the manufacturers’ protocols. One microgram
of total RNA was reversely transcribed for single-stranded cDNA
using oligo(dT)12 18 primer (GE Healthcare, Buckinghamshire,
UK) with Superscript II reverse transcriptase (Invitrogen,
Carlsbad, CA, USA). Quantitative PCR was carried out using
the LightCycler 480 System (Roche Diagnostics, Indianapolis, IN,
USA). The probes and primers for MRGBP and hypoxanthine
phosphoribosyltransferase1 (HPRT1) are as follows – MRGBP:
forward, 50-GGAGGAGACAGTGGTGTGG-30, reverse, 50-CATGTG
GAAGTGTCGGTTCA-30, and probe, Universal ProbeLibrary #39
(Roche Diagnostics); HPRT1: forward, 50-TGACCTTGATTTATTT
TGCATACC-30, reverse, 50-CGAGCAAGACGTTCAGTCCT-30, and
probe, Universal ProbeLibrary #73 (Roche Diagnostics).
Northern blot analysis
HEK293 cells transfected with pCAGGS-HA-bromodomain con-
taining 8 (BRD8) and/or pcDNA-Myc/His-MRGBP were harvested
at the indicated time points after transfection. After purification
of RNA, 1mg of poly(A) RNA was separated on a 1% agarose
gel containing formaldehyde and transferred to a nylon mem-
brane. The blot was hybridised with
32P-labeled PCR product
of MRGBP or b-actin cDNA. Human multiple-tissue northern
blots were obtained from BD Biosciences (Palo Alto, CA, USA),
and analysed according to the instructions of the manufacturer.
The blots were autoradiographed with intensifying screens at
 801C for 5 days.
Knockdown of endogenous MRGBP expression by RNA
interference
Plasmids expressing short hairpin RNA (shRNA) to MRGBP
(psiH1BX-MRGBPs), BRD8 (psiH1BX-BRD8), or EGFP (psiH1BX-
EGFP) were prepared as described earlier (Shimokawa et al, 2003).
Briefly, psiH1BX-MRGBPs and psiH1BX-BRD8 were constructed
by the cloning of double-stranded oligonucleotides into psiH1BX
vector and the target sequences of synthetic oligonucleotides for
MRGBP shRNAs were as follows: 50-GAGAAUUUGUAGCGGUUA
U-30 for shMRGBP#1, 50-GUGACAUGGAUUAGCGCUA-30 for
shMRGBP#2, 50-ACAAAGUCCUGACCGCAAA-30 for shMRGBP#3,
50-GGGAGAAGUGGUGGAAACU-30 for shBRD8. To evaluate the
knockdown effect on MRGBP and BRD8, SW480 and HCT116 cells
were transfected with these shRNA constructs using Nucleofector
kit (Amaxa, Gaithersburg, MD, USA), and western blotting was
performed. For cell proliferation assay, psiH1BX-MRGBPs,
psiH1BX-BRD8, or psiH1BX-EGFP were transfected into SW480
and HCT116 cells using FuGENE6 (Roche Diagnostics) according
to the manufacturer’s protocol. Transfectants were selected in
appropriate concentration of Geneticin (SW480: 1.25mgml
–1,
HCT116: 0.7mgml
–1 for 7–9 days), and the viable cells were
measured by WST-8 assay (Dojindo, Kumamoto, Japan). Control
(ON-TARGETplus Non-Targeting pool, Dharmacon, Lafayette, CO,
USA) and a mixture of four MRGBP-specific On-Targetplus siRNA
oligos (50-GAGAAUUUGUAGCGGUUAU-30,5 0-GUGACAUGGAU
UAGCGCUA-30,5 0-ACAAAGUCCUGACCGCAAA-30, and 50-CAGG
GAAAACCUCGGAUUA-30) were also used for the functional
analysis.
Flow cytometry
Cultured colorectal cancer cells were transfected with control or
MRBGP siRNA (Dharmacon) for 48h. For analysis of cellular DNA
content, transfected cells were collected and fixed with 70%
ethanol, and then kept at  201C before use. Cells were incubated
with 2mgml
–1 RNase A at 371C for 30min and stained with
propidium iodide (PI) at room temperature for 30min. Assess-
ment of apoptosis by annexin V and PI double staining was
performed using Annexin V-FITC Apoptosis Detection kit
(Medical & Biological Laboratories, Nagoya, Japan). Cellular
DNA synthesis was evaluated by incorporation of 5-ethynyl-20-
deoxyuridine (EdU) using Click-iT EdU Flow Cytometry Assay kit
(Invitrogen). Briefly, transfected cells were cultured in media
containing 10mM EdU for 30min. The incorporated EdU and total
DNA were stained with Alexa448-conjugated azide and 7-amino-
actinomycin D (7-AAD), respectively. Subsequently, the cell
suspensions were analysed on an FACSCalibur (Becton Dickinson,
Franklin Lakes, NJ, USA) using FlowJo software (Tree Star,
Ashland, OR, USA).
Construction of plasmids expressing MRGBP and BRD8
The entire coding region of MRGBP and BRD8 were amplified by
RT–PCR using gene-specific primer sets. The primer sequences
used for the amplification were 50-TGTGAATTCGCCATGGGAGA
GGC-30 (forward) and 50-TAACTCGAGCGTGCGGCGCCGCTT-30
(reverse) for MRGBP, and 50-ATAGAATTCTCTTCTGTCATGAGA
AGTGG-30 (forward) and 50-ATACTCGAGTCACTTTTTCATCTT
C-30 (reverse) for BRD8. The cDNA products of MRGBP and BRD8
were cloned into an appropriate cloning site of pcDNA3.1-Myc/His
(Invitrogen) or pCAGGS-HA vector, respectively. DNA sequences
of all constructs were confirmed by DNA sequencing (ABI3730,
Applied Biosystems, Foster City, CA, USA).
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against MRGBP
We prepared histidine-tagged human MRGBP protein in bacteria,
and raised rabbit antibodies specific to MRGBP by immunising
rabbits with the MRGBP protein. Purification of antibodies was
carried out with standard protocols using affinity columns
(Affi-Gel 15, Bio-Rad, Hercules, CA, USA). Specificity of the
antibodies was examined by immunoblot analysis using whole
extracts from cells expressing Myc-tagged MRGBP (data not
shown). Immunohistochemical staining was performed using anti-
MRGBP polyclonal antibody. Paraffin-embedded tissue sections
were subjected to the SAB-PO peroxidase immunostaining
system according to the instructions of the manufacturer (Nichirei,
Tokyo, Japan).
Immunoprecipitation and western blot analysis
COS7 and HEK293 cells were transfected with pcDNA-Myc/His-
MRGBP, pCAGGS-HA-BRD8, or the combination using FuGENE6.
For immunoprecipitation, the cells were lysed in 0.5% Nonidet
P-40 buffer (10mM Tris–HCl pH 7.5, 150mM NaCl) supplemented
with a Protease Inhibitor Cocktail Set III (Calbiochem,
San Diego, CA, USA). The whole-cell extract was incubated with
anti-Myc (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or
anti-HA antibody (Roche Diagnostics), followed by Protein
G-Sepharose beads (Invitrogen) at 41C. Proteins were separated
by SDS–PAGE and immunoblot analysis was performed. Horse-
radish peroxidase-conjugated goat anti-mouse IgG (GE Health-
care) and goat anti-rat IgG (Santa Cruz Biotechnology) served as
the secondary antibody for the ECL Detection System (GE
Healthcare). To examine the endogenous interaction of MRGBP
and BRD8, nuclear extract from SW480 cells was incubated with
anti-MRGBP or anti-p120 (BRD8) antibody (Abcam, Cambridge,
UK), followed by Protein G-Sepharose beads overnight at
41C. After washing, these immunoprecipitants were applied for
SDS–PAGE. Normal rabbit IgG (Santa Cruz Biotechnology) was
used as negative control.
Immunocytochemical staining
COS7 cells were transfected with pcDNA-Myc/His-MRGBP,
pCAGGS-HA-BRD8, or the combination of the two. Twenty-four
hours after transfection, the cells fixed with 4% paraformaldehyde
were rendered permeable with PBS containing 0.1% Triton X-100.
Subsequently, the cells were covered with 3% BSA in PBS to block
non-specific hybridisation, and incubated with anti-Myc or anti-
HA antibody. The reaction was visualised after incubation with
Alexa Fluor 488 anti-mouse or Alexa Fluor 594 anti-rat secondary
antibody (Invitrogen). Nuclei were counterstained with 40,60-
diamidine-20-phenylindole dihydrochloride.
RESULTS
Expression of MRGBP is frequently elevated in colorectal
tumours
We have earlier compared expression profiles of colorectal cancers
with the corresponding non-cancerous colon tissues using cDNA
microarray and identified a number of up-regulated genes in the
cancer cells (Lin et al, 2002). In this study, we investigated a gene
termed as MRGBP (formally C20orf20), because its expression was
elevated in 9 out of 11 tumours in our microarray data. Reportedly,
MRGBP is a subunit of a transcriptional complex of TRRAP/TIP60.
Subsequent quantitative PCR confirmed its elevated expression in
10 out of the additional 15 colorectal tumours compared with their
matched non-cancerous mucosa (Figure 1A). Western blot analysis
also showed enhanced MRGBP expression in 10 out of the
additional 14 tumours examined (Figure 1B). Multiple tissue
northern blot analysis using MRGBP cDNA as a probe detected a
1.6kb transcript that was readily detectable in the skeletal muscle,
testis, and thyroid, whereas it showed a relatively low level of
expression in important normal organs such as heart, brain, lung,
liver, and kidney (Figure 1C).
To further evaluate its expression levels, we performed
immunohistochemical staining using 27 colorectal cancer tissues.
As a result, we observed accumulated MRGBP mainly in the
nucleus of cancer cells in 20 out of the 27 tumours. However, non-
cancerous epithelial cells in the adjacent mucosa of the tumours
did not show accumulation of MRGBP (Figure 1D).
MRGBP confers growth-promoting effect to cancer cells
To investigate a possible function of elevated MRGBP expression
in the proliferation of cancer cells, we prepared plasmids that
express MRGBP- and EGFP-specific shRNAs with neomycin
resistant gene (psiH1BX-MRGBP1, -MRGBP2, -MRGBP3, and
-EGFP). Transfection of SW480 or HCT116 cells with all psiH1BX-
MRGBPs significantly reduced the MRGBP expression in the cells,
whereas that with control plasmid (psiH1BX-EGFP) did not affect
MRGBP expression (data not shown). Cells transfected with
psiH1BX-MRGBPs or psiH1BX-EGFP were cultured in media
containing appropriate concentration of geneticin, and the number
of viable cells was examined at day 7 or 9 after the transfection. As
a result, psiH1BX-MRGBPs significantly reduced the number of
viable cells compared with control plasmid (Figure 2A and B). To
disclose the mechanism(s) underlying the decrease of viable cells
by MRGBP knockdown, we investigated induction of apoptosis,
cell cycle progression, and DNA synthesis in cancer cells treated
with MRGBP siRNA. Knockdown of MRGBP did not influence
significantly on population of apoptotic cells (data not shown). On
the other hand, cell cycle analysis showed that treatment of
HCT116 and SW480 cells with MRGBP siRNA significantly reduced
cell population in S-phase compared with control siRNA
(35.4±2.0% vs 17.5±1.2% in HCT116, P¼0.0002; 29.4±1.3% vs
26.4±0.2% in SW480, P¼0.016). Consistently, DNA synthesis was
suppressed by MRGBP siRNA compared with control siRNA
(Figure 2C). These results suggested that MRGBP might have an
essential function in proliferation of colorectal cancer cells through
regulation of cell cycle.
Identification of bromodomain containing 8 as an
MRGBP-interacting protein
To further investigate the function of MRGBP, we performed yeast
two-hybrid screening and identified BRD8 (also known as skeletal
muscle abundant protein (SMAP) and p120) as an MRGBP-
interacting protein (data not shown). As all 32 positive clones
contained the C-terminal region of BRD8, the region was likely to
be responsible for the interaction. To confirm the interaction
between MRGBP and BRD8, immunoprecipitation assay was
performed using plasmids expressing Myc/His-tagged MRGBP
(pcDNA-Myc/His-MRGBP) and HA-tagged BRD8 (pCAGGS-HA-
BRD8). When COS7 cells were transfected with both pcDNA-Myc/
His-MRGBP and pCAGGS-HA-BRD8, immunoprecipitation with
anti-HA antibody followed by immunoblotting with anti-Myc
antibody showed a single band corresponding to Myc-tagged
MRGBP. Consistently, immunoprecipitation with anti-Myc anti-
body co-precipitated HA-tagged BRD8 (Figure 3A). We further
examined endogenous interaction of MRGBP with BRD8 using
nuclear extract from SW480 cells. As shown in Figure 3B (upper
panels), immunoprecipitation with anti-MRGBP antibody co-
precipitated endogenous BRD8. In addition, usage of anti-BRD8
antibody for immunoprecipitation also showed interacting endo-
genous MRGBP with BRD8 (Figure 3B, lower panels). BRD8 has
been reported to express three transcript variants. Isoform 1 of
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Isoform 2 encodes a protein with a longer and different C-terminal
region compared with isoform 1. Although BRD8 isoform 1
contains one bromodomain, isoform 2 contains two. We
additionally performed immunoprecipitation experiment using
isoform 2 expression plasmid. As a result, isoform 2 also interacted
with MRGBP (Supplementary Figure 1A).
Responsible region of MRGBP for the interaction with
BRD8
To address the responsible region of MRGBP for the interaction
with BRD8, we prepared various deletion mutants of MRGBP
(Figure 3C). Immunoprecipitation and subsequent immunoblot
analysis disclosed that wild type and MRGBPD1, an N-terminal
deletion mutant containing codons 24–204 bound with BRD8.
However, MRGBPD2 containing codons 44–204 did not associate
with BRD8. In addition, MRGBPD4, another deletion mutant
containing codons 1–90 interacted with BRD8, whereas MRGBPD3
containing codons 1–76 did not (Figure 3C). These data indicated
that codons 24–90 could be essential for the interaction.
MRGBP increases BRD8 protein in a post-transcriptional
manner
To examine the levels of BRD8 expression resulting from the
interaction with MRGBP, we carried out western blot analysis.
Compared with cells expressing exogenous BRD8 alone, the
presence of MRGBP markedly enhanced expression of BRD8.
The induced BRD8 expression was dependent on the time of
transfection, with a continuous increase up to 48h. In contrast, the
levels of BRD8 were unchanged without MRGBP (Figure 4A, upper
panels). We also analysed BRD8 mRNA in the cells by northern
blot analysis. As shown in Figure 4A (lower panels), the levels of
BRD8 mRNA were not affected by MRGBP, indicating that the
MRGBP-induced BRD8 protein results from post-transcriptional
mechanisms. As another experiment showed that MG132, a protea-
some inhibitor, greatly enhanced BRD8 protein (Supplementary
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Figure 1 MRGBP is overexpressed in human colorectal tumours. (A) Relative expression of MRGBP in 15 additional colorectal tumours and the
corresponding non-cancerous mucosa was analysed by real-time PCR. Quantity of MRGBP was normalised to HPRT1 expression. The y axis indicates the
ratio of mean of MRGBP expression in tumour to that in normal tissues. The data represents mean±s.d. from three independent experiments. (B)
Representative western blotting result of MRGBP in normal and tumour tissues from human colon. Expression of b-actin served as a control. (C) Multiple-
tissue northern blot analysis of MRGBP in a panel of 23 normal human adult tissues. Expression of b-actin served as a control. (D) Representative images of
immunohistochemical staining of MRGBP in normal and tumour tissues from human colon. Magnification:  100.
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regulating BRD8 expression. Consistent with this view, wild type
and mutant MRGBP (D1 and D4) that associated with BRD8
increased BRD8 expression (Figure 3C). However, mutant MRGBP
(MRGBPD2 and D3) lacking the binding ability with BRD8 did not
enhance BRD8 expression (Figure 3C). To confirm the evidence
that MRGBP regulates BRD8 expression, we finally knocked down
endogenous MRGBP using siRNA. In complete agreement with the
result of elevated BRD8 expression by MRGBP, knockdown of
MRGBP substantially down-regulated BRD8 expression
(Figure 4B). These results identified BRD8 as a novel down-stream
target of MRGBP.
DISCUSSION
We have shown for the first time that MRGBP (C20orf20) is up-
regulated in the majority of colorectal cancer, and that its elevated
expression is implicated in the proliferation of cancer cells. In
addition, we have discovered that MRGBP associates with BRD8.
Analysis of TRRAP/TIP60 complex by mass spectrometry identi-
fied a number of components including MRGBP (Cai et al, 2003).
Consistent with our finding, BRD8 was also included in the
complex (Cai et al, 2003). As all positive yeast clones contained
bromodomain in the C-terminal region, bromodomain might be
responsible for the binding. Three alternatively spliced forms of
BRD8 transcripts have been reported, and all forms include one or
two bromodomains at their C-terminal. The predominant variant
of transcripts encodes p120 (BRD8 isoform 1), a coactivating
factor for thyroid hormone receptor (Monden et al, 1997).
Interestingly, p120 was also found to interact with PPARg/RXR
heterodimer on PPAR-response elements in the presence of the
ligand (Monden et al, 1999), suggesting that p120 should be
involved in transcriptional regulation. BRD8 isoform 2 contains
two bromodomains and has a longer C-terminus compared
with p120. Variant 3 encodes SMAP (or BRD8 isoform 3), which
was isolated as a highly expressed transcript in skeletal muscle
(Nielsen et al, 1996). However, the function of SMAP has not
been clarified. In addition to isoform 1, we confirmed that
MRGBP associates with isoform 2. As isoform 3 shares the same
bromodomain with isoform 1, MRGBP should also interact with
isoform 3.
In this study, we also examined co-localisation of MRGBP and
BRD8 by immunocytochemical staining (Supplementary Figure 2).
Consistent with the data of immunohistochemical analysis of
MRGBP, exogenous MRGBP protein was accumulated in the
nucleus of COS7 cells (Supplementary Figure 2A). On the other
hand, BRD8 was mainly localised in the cytoplasm (Supplementary
Figure 2B). Interestingly, when COS7 cells were transfected with
both plasmids expressing BRD8 and MRGBP, BRD8 accumulated
in the nucleus and co-localised with MRGBP (Supplementary
Figure 2C). These data implicate that MRGBP alters subcellular
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Figure 2 Effect of MRGBP shRNA on the proliferation of colorectal cancer cells. (A) SW480 and (B) HCT116 cells were treated with MRGBP shRNAs or
EGFP shRNA (control) for 48h, and western blot analysis was performed. Expression of b-actin served as a control. Viability of cells transfected with shRNAs
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Student’s t-test; *, Po0.05; ***, Po0.001, vs EGFP shRNA-transfected cells. (C) SW480 and HCT116 cells were treated with control or MRGBP siRNA for
48h, and then were incubated with 10mM EdU for 30min. Representative flow cytometric results of HCT116 cells without EdU incorporation (left) and the
cells transfected with control siRNA (middle) or MRGBP siRNA (right) were shown. The data represents mean±s.d. from three independent transfections.
A significant difference was determined by Student’s t-test.
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slocalisation of BRD8 and that it increases BRD8 expression in a
post-transcriptional manner. As proteasome inhibitor MG132
strikingly augmented BRD8 expression, BRD8 protein is likely to
be easily degraded in the proteasome (Supplementary Figure 1B).
Taken together, these data suggest that MRGBP may regulate the
stability of BRD8. We also found that the interaction of MRGBP with
BRD8 is essential for the MRGBP-induced BRD8 accumulation
(Figure 3C). Therefore, MRGBP may participate in the shuttling of
BRD8 into the nucleus in which proteolysis machinery is inactive.
Furthermore, to address the function of BRD8 on cell proliferation,
we conducted cell proliferation experiment using BRD8 shRNA
construct. Treatment of HCT116 cells with BRD8 or control shRNA
showed that proliferation of HCT116 cells was significantly reduced
by BRD8 shRNA compared with control shRNA (Supplementary
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Figure 3 Interaction between MRGBP and BRD8. (A) COS7 cells were transfected with pcDNA-Myc/His-MRGBP, pCAGGS-HA-BRD8, or the
combination of the two. Extracts from these cells were immunoprecipitated with anti-HA (upper two panels) or anti-Myc antibody (lower two panels). (B)
Nuclear extract from SW480 cells were immunoprecipitated with anti-MRGBP (upper two panels) or anti-BRD8 antibody (lower two panels). Western blot
analysis was performed using the indicated antibodies. (C) Interaction of wild type or the deletion mutants of MRGBP with BRD8. HEK293 cells were
transfected with HA-tagged BRD8 plasmid and wild type or several deletion mutants of Myc-tagged MRGBP plasmids. Extracts from these cells were
immunoprecipitated with anti-Myc antibody and then immunoblotted with anti-HA antibody (upper panel). Expressions of HA-tagged BRD8 and b-actin
were shown in the middle panel and the lower panel, respectively.
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Figure 4 MRGBP increases expression of BRD8 protein in a post-transcriptional manner. (A) HEK293 cells were transfected with pcDNA-Myc/His-
MRGBP and/or pCAGGS-HA-BRD8. After transfection, the cells were harvested at the indicated time points, and western blot analysis was performed
(upper two panels). Expression of b-actin served as a control. Simultaneous northern blot analysis using BRD8 or b-actin cDNA as a probe was performed
(lower two panels). Expression of b-actin served as a control. (B) Effect of knockdown of MRGBP on BRD8 expression. HCT116 cells were transfected with
MRGBP-specific or control siRNA for 72h. Nuclear extracts were isolated, and western blot analysis was performed using the indicated antibodies.
Expression of Histone H3 served as a control.
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sFigure 2D). Therefore, BRD8 may have an important function for cell
proliferation as a down-stream target of MRGBP in cancer cells.
Although this hypothesis should be investigated in future studies,
our findings have uncovered a novel function of MRGBP that is a
member of the TRRAP/TIP60 complex.
In summary, the expression of MRGBP is enhanced in the
majority of colorectal cancers, and its expression is associated with
the growth of cancer cells. Interaction of MRGBP with BRD8 is
probably a key for determination of MRGBP function in cancer
cells. Our findings will be helpful for the profound understanding
of colorectal carcinogenesis and may contribute to the develop-
ment of novel anti-cancer drugs.
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